Do you offer somatostatin analogues (eg lanreotide, octreotide) to asymptomatic patients with metastatic, nonfunctioning, well-differentiated enteropancreatic neuroendrocrine tumors?

Topics: Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors • Neuroendocrine Tumors

Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID and CLARINET trials, how do you decide when to treat?

Answer from: Medical Oncologist at Academic Institution

I do use SSA in non-functional NET because of the clear PFS benefit observed. There is a difference between whether a drug may have OS benefit in a particular setting vs whether it is possible to demonstrate it in a clinical trial. Please see our position paper:Future directions in the treatment of ...

Comments

Medical Oncologist at UH Seidman Cancer Center, Case Western Reserve University
How about those with met. non-functional asymptoma...

Related Questions